Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAELO phase 3 study of NTLA-2002 in hereditary angioedema
2024-515741-42-00Phase 3Authorised
- Sponsor
- Intellia Therapeutics
- Start
- Mar 2025
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in hereditary angioedema (HAE) comparing NTLA-2002 with Placebo (2 arms). Primary endpoint: Time-normalized number of Investigator-confirmed HAE attacks from Week 5 through Week 28. Planned start Mar 2025; status: authorised.
02
Drugs
lonvoguran
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2024-515741-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515741-42-00.